<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 3; Issue 3</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(May-Jun, 2022)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Hepatic Encephalopathy: An Overview of Basic Concepts and Mechanisms</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>19</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Abdelaati El</FirstName>
          <LastName>Khiat</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Omar El</FirstName>
          <LastName>Hiba</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Abdelmohcine</FirstName>
          <LastName>Aimrane</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Ahmed</FirstName>
          <LastName>Draoui</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Arumugam Radhakrishnan</FirstName>
          <LastName>Jayakumar</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Michael D.</FirstName>
          <LastName>Norenberg</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Halima</FirstName>
          <LastName>Gamrani</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>The liver failure induced encephalopathy is commonly referred as hepatic encephalopathy (HE). For many decades, scientists have tried to describe the symptoms of this disorder revealing a spectrum with different types of HE. Studies on the mechanisms underlying the pathogenesis of HE have implicated several factors, mainly neurotoxins, including ammonia, manganese, in addition to changes in various physiological factors, especially an imbalance between true and false neurotransmitters, as well as the involvement of various pro-inflammatory mediators. Such changes impact on the brain, which promote disorders in glia and neurons. This review focuses on the most relevant basic pathophysiologic mechanisms associated with HE.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Hepatic Encephalopathy,Pathophysiology,Liver Failure,Ammonia</Keywords>
      <URLs>
        <Abstract>https://www.jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13698&amp;title=Hepatic Encephalopathy: An Overview of Basic Concepts and Mechanisms</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>Aggarwal A, Vaidya S, Shah S, Singh J, Desai S, Bhatt M. Reversible Parkinsonism and T1W pallidal hyperintensities in acute liver failure. Mov Disord Off J Mov Disord Soc 2006; 21: 1986–1990.&#13;
&#13;
Aschner M, Gannon M, Kimelberg HK. Manganese uptake and efflux in cultured rat astrocytes. J Neurochem 1992; 58: 730–735.&#13;
&#13;
Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev 1991; 43: 27–71.&#13;
&#13;
Bengtsson F, Bugge M, Johansen KH, Butterworth RF. Brain tryptophan hydroxylation in the portacaval shunted rat: a hypothesis for the regulation of serotonin turnover in vivo. J Neurochem 1991; 56: 1069–1074.&#13;
&#13;
Bergeron M, Swain MS, Reader TA, Grondin L, Butterworth RF. Effect of Ammonia on Brain Serotonin Metabolism in Relation to Function in the Portacaval Shunted Rat. J Neurochem 1990; 55: 222–229.&#13;
&#13;
Bergqvist PBF, Hjorth S, Apelqvist G, Bengtsson F. Potassium-evoked neuronal release of serotonin in experimental chronic portal-systemic encephalopathy. Metab Brain Dis 1997; 12: 193–202.&#13;
&#13;
Blei DA and Cordoba J. Hepatic encephalopathy. Rom J Gastroenterol 2002; 11: 163–165.&#13;
&#13;
Bloch P, Delorme ML, Rapin JR, Granger A, Boschat M, Opolon P. Reversible modifications of neurotransmitters of the brain in experimental acute hepatic coma. Surg Gynecol Obstet 1978; 146: 551–558.&#13;
&#13;
Butterworth RF, Giguand;egrave;re JF, Michaud J, Lavoie J, Layrargues GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol 1987; 6: 1–12.&#13;
&#13;
Butterworth RF, Norenberg MD, Felipo V, Ferenci P, Albrecht J, Blei AT. Experimental models of hepatic encephalopathy: ISHEN guidelines. Liver Int 2009; 29: 783–788.&#13;
&#13;
Butterworth RF. Neuroinflammation in acute liver failure: mechanisms and novel therapeutic targets. Neurochem Int 2011; 59: 830–836.&#13;
&#13;
Butterworth RF. Portal-systemic encephalopathy: a disorder of neuron-astrocytic metabolic trafficking. Dev Neurosci 1993; 15: 313–319.&#13;
&#13;
Butterworth RF. The liver–brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 2013; 10: 522.&#13;
&#13;
Butz M, Timmermann L, Braun M, Groiss SJ, Wojtecki L, Ostrowski S, et al. Motor impairment in liver cirrhosis without and with minimal hepatic encephalopathy. Acta Neurol Scand 2010; 122: 27–35.&#13;
&#13;
Buxton BH, Stewart DA, Murray-Lyon IM, Curzon G, Williams R. Plasma amino acids in experimental acute hepatic failure and their relationship to brain tryptophan. Clin Sci 1974; 46: 559–562.&#13;
&#13;
Chastre A, Band;eacute;langer M, Beauchesne E, Nguyen BN, Desjardins P, Butterworth RF. Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. PLoS One 2012; 7: e49670.&#13;
&#13;
Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute E liver failure is correlated with arterial ammonia concentration. Hepatology 1999; 29: 648–653.&#13;
&#13;
Cand;oacute;rdoba-Aguilar A. Dragonflies and damselflies: model organisms for ecological and evolutionary research. OUP Oxford; 2008.&#13;
&#13;
de Franand;ccedil;a MER and Peixoto CA. cGMP signaling pathway in hepatic encephalopathy neuroinflammation and cognition. Int Immunopharmacol 2020; 79: 106082.&#13;
&#13;
Dejong CHC, Kampman MT, Deutz NEP, Soeters PB. Cerebral cortex ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J Neurochem 1992; 59: 1071–1079.&#13;
&#13;
Dodsworth JM, James JH, Cummings MC, Fischer JE. Depletion of brain norepinephrine in acute hepatic coma. Surgery 1974; 75: 811–820.&#13;
&#13;
El Hiba O, Elgot A, Ahboucha S, Gamrani H. Differential regional responsiveness of astroglia in mild hepatic encephalopathy: An Immunohistochemical approach in bile duct ligated rat. Acta Histochem 2016; 118: 338–346.&#13;
&#13;
El Hiba O, Gamrani H, Ahboucha S. Increased Reissner’s fiber material in the subcommissural organ and ventricular area in bile duct ligated rats. Acta Histochem 2012; 114: 673–681.&#13;
&#13;
El Khiat A, Tamegart L, Draoui A, El Fari R, Sellami S, Rais H, El Hiba O, Gamrani H. Kinetic deterioration of short memory in rat with acute hepatic encephalopathy: Involvement of astroglial and neuronal dysfunctions. Behav Brain Res 2019; 367: 201–209.&#13;
&#13;
Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716–721.&#13;
&#13;
Fischer J and Baldessarini R. False neurotransmitters and hepatic failure. Lancet 1971; 298: 75–80.&#13;
&#13;
Funakoshi N and Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Hand;eacute;pato-Gastro Oncol Dig 2013; 20: 822–828.&#13;
&#13;
Ghabril M, Zupanets IA, Vierling J, Mantry P, Rockey D, Wolf D, et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: a pilot study of safety and effect on venous ammonia concentration. Clin Pharmacol Drug Dev 2013; 2: 278–284.&#13;
&#13;
Girard G, Giguand;egrave;re JF, Butterworth RF. Region-selective reductions in activities of glutamine synthetase in rat brain following portacaval anastomosis. Metab Brain Dis 1993; 8: 207–215.&#13;
&#13;
Goulenok C, Bernard B, Cadranel JF, Thabut D, Di Martino V, Opolon P, Poynard T. Flumazenil vs. placebo in hepatic encephalopathy in patients with cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2002; 16: 361–372.&#13;
&#13;
Hadesman R, Wiesner RH, Go VLW, Tyce GM. Concentrations of 3,4-dihydroxyphenylalanine and catecholamines and metabolites in brain in an anhepatic model of hepatic encephalopathy. J Neurochem 1995; 65: 1166–1175.&#13;
&#13;
Hahn M, Massen O, Nencki M, Pawlow J. Die Eck’sche Fistel zwischen der unteren Hohlvene und der Pfortader und ihre Folgen fand;uuml;r den Organismus. Arch fand;uuml;r Exp Pathol und Pharmakologie 1893; 32: 161–210.&#13;
&#13;
Hand;auml;ussinger D, Kircheis G, Fischer R, Schliess F, vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema? J Hepatol 2000; 32: 1035–1038.&#13;
&#13;
Hazell AS and Butterworth RF. Hepatic encephalopathy: An update of pathophysiologic mechanisms. Proc Soc Exp Biol Med 1999; 222: 99–112.&#13;
&#13;
Hazell AS and Norenberg MD. Manganese decreases glutamate uptake in cultured astrocytes. Neurochem Res 1997; 22: 1443–1447.&#13;
&#13;
Hazell AS, Normandin L, Norenberg MD, Kennedy G, Yi J-H. Alzheimer type II astrocytic changes following sub-acute exposure to manganese and its prevention by antioxidant treatment. Neurosci Lett 2006; 396: 167–171.&#13;
&#13;
Hermann B, Santiago A, Mouri S, Thabut D, Weiss N. Nouveautand;eacute;s dans l’encand;eacute;phalopathie hand;eacute;patique: de l’encand;eacute;phalopathie hand;eacute;patique minimale and;agrave; l’encand;eacute;phalopathie hand;eacute;patique clinique. Prat Neurol 2018; 9: 1–12.&#13;
&#13;
Hori K, Wada A, Shibuta T. Changes in Phenoloxidase Activities of the Galls on Leaves of Ulmus davidana Formed by Tetraneura fuslformis (Homoptera: Eriosomatidae). Appl Entomol Zool 1997; 32: 365–371.&#13;
&#13;
Inoue E, Hori S, Narumi Y, Fujita M, Kuriyama K, Kadota T, Kuroda CH. Portal-systemic encephalopathy: presence of basal ganglia lesions with high signal intensity on MR images. Radiology 1991; 179: 551–555.&#13;
&#13;
Jalan R and Williams R. The inflammatory basis of intracranial hypertension in acute liver failure. J Hepatol 2001; 34: 940–942.&#13;
&#13;
Jayakumar AR, Rao KVR, Norenberg MD. Neuroinflammation in hepatic encephalopathy: mechanistic aspects. J Clin Exp Hepatol 2015; 5: S21–S28.&#13;
&#13;
Jiang W, Desjardins P, Butterworth RF. Direct evidence for central proinflammatory mechanisms in rats with experimental acute liver failure: protective effect of hypothermia. J Cereb Blood Flow Metab 2009; 29: 944–952.&#13;
&#13;
Keane HM, Sheron N, Goka J, Hughes RD, Williams R. Plasma inhibitory activity against tumour necrosis factor in fulminant hepatic failure. Clin Sci 1996; 90: 77–80.&#13;
&#13;
Knecht K, Michalak A, Rose C, Rothstein JD, Butterworth RF. Decreased glutamate transporter (GLT-1) expression in frontal cortex of rats with acute liver failure. Neurosci Lett 1997; 229: 201–203.&#13;
&#13;
Krieger D, Krieger S, Theilmann L, Jansen O, Gass P, Lichtnecker H. Manganese and chronic hepatic encephalopathy. Lancet 1995; 346: 270–274.&#13;
&#13;
Kulisevsky J, Pujol J, Balanzand;oacute; J, Junquand;eacute; C, Deus J, Capdevilla A, Villanueva C. Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: clinical correlations. Hepatology 1992; 16: 1382–1388.&#13;
&#13;
Larsen FS, Gottstein J, Blei AT. Cerebral hyperemia and nitric oxide synthase in rats with ammonia-induced brain edema. J Hepatol 2001; 34: 548–554.&#13;
&#13;
Lockwood AH, Weissenborn K, Butterworth RF. An image of the brain in patients with liver disease. Curr Opin Neurol 1997; 10: 525–533.&#13;
&#13;
Lockwood AH, Yap EWH, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337–341.&#13;
&#13;
Michalak A, Chatauret N, Butterworth RF. Evidence for a serotonin transporter deficit in experimental acute liver failure. Neurochem Int 2001; 38: 163–168.&#13;
&#13;
Michalak A, Rose C, Buu PN, Butterworth RF. Evidence for altered central noradrenergic function in experimental acute liver failure in the rat. Hepatology 1998; 27: 362–368.&#13;
&#13;
Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients: A randomised, cross-over study. J Hepatol 1989; 8: 208–217.&#13;
&#13;
Mousseau DD, Baker GB, Butterworth RF. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J Neurochem 1997; 68: 1200–1208.&#13;
&#13;
Mousseau DD, Perney P, Layrargues GP, Butterworth RF. Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett 1993; 162: 192–196.&#13;
&#13;
Mullen KD and Jones EA. Natural benzodiazepines and hepatic encephalopathy. In: Seminars in liver disease. © 1996 by Thieme Medical Publishers, Inc.; 1996. p. 255–264.&#13;
&#13;
Munoz SJ. Hepatic encephalopathy. Med Clin North Am 2008; 92: 795–812.&#13;
&#13;
Murakami N, Saito K, Kato T, Nakamura T, Moriwaki H, Muto Y. Changes in brain monoamine metabolism in rats with acute ischemic hepatic failure under artificial cardiopulmonary management. Gastroenterol Jpn 1992; 27: 191–198.&#13;
&#13;
Muto Y, Meager A, Nouri-Aria K, Alexander GM, Eddleston AWF, Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988; 332: 72–74.&#13;
&#13;
Naegele T, Grodd W, Viebahn R, Seeger U, Klose U, Seitz D, Kaiser S, Mader I, Mayer J, Lauchart W, Gregor M. MR imaging and 1H spectroscopy of brain metabolites in hepatic encephalopathy: time-course of renormalization after liver transplantation. Radiology 2000; 216: 683–691.&#13;
&#13;
Nencki M, Pawlow JP, Zaleski J. Ueber den Ammoniakgehalt des Blutes und der Organe und die Harnstoffbildung bei den Sand;auml;ugethieren. Naunyn Schmiedebergs Arch Pharmacol 1895; 37: 26–51.&#13;
&#13;
Newland MC, Ceckler TL, Kordower JH, Weiss B. Visualizing manganese in the primate basal ganglia with magnetic resonance imaging. Exp Neurol 1989; 106: 251–258.&#13;
&#13;
Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol 2003; 38: 441–446.&#13;
&#13;
Norenberg MD. Astrocytic-ammonia interactions in hepatic encephalopathy. In: Seminars in liver disease. © 1996 by Thieme Medical Publishers, Inc.; 1996. p. 245–53.&#13;
&#13;
Norenberg MD. The role of astrocytes in hepatic encephalopathy. Neurochem Pathol 1987; 6: 13–33.&#13;
&#13;
Ong JP, Aggarwal A, Krieger D, Easley KA, Karafa MT, Van Lente F, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188–193.&#13;
&#13;
Orlowski M, Sessa G, Green JP. and;gamma;-Glutamyl transpeptidase in brain capillaries: possible site of a blood-brain barrier for amino acids. Science 1974; 184: 66–68.&#13;
&#13;
Palomero-Gallagher N and Zilles K. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys 2013; 536: 109–121.&#13;
&#13;
Pentschew A, Ebner FF, Kovatch RM. Experimental manganese encephalopathy in monkeys: a preliminary report. J Neuropathol Exp Neurol 1963; 22: 488–499.&#13;
&#13;
Pomierlayrargues G, Giguand;egrave;re JF, Lavoie J, Gagnon S, Damour M, Cailland;eacute; G, Wells J, Butterworth RF. Efficacy of ro-15-1788 in cirrhotic-patients with hepatic-coma-results of a randomized double-blind placebo-controlled crossover trial. In: Hepatology. Wb saunders co independence square west curtis center, ste 300, Philadelphia. 1992. p. A122–A122.&#13;
&#13;
Prakash R and Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515.&#13;
&#13;
Pujol A, Pujol J, Graus F, Rimola A, Peri J, Mercader JM, et al. Hyperintense globus pallidus on T1-weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology 1993; 43: 65.&#13;
&#13;
Rao VLR, Giguand;egrave;re JF, Layrargues GP, Butterworth RF. Increased activities of MAOA and MAOB in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Brain Res 1993; 621: 349–352.&#13;
&#13;
Rolando N, Wade JIM, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 2000; 32: 734–739.&#13;
&#13;
Rose C, Butterworth RF, Zayed J, Normandin L, Todd K, Michalak A, Spahr L, Huet PM, Pomier–Layrargues G. Manganese deposition in basal ganglia structures results from both portal-systemic shunting and liver dysfunction. Gastroenterology 1999; 117: 640–644.&#13;
&#13;
Schafer D and Jones EA. Hepatic encephalopathy and the and;gamma;-aminobutyric-acid neurotransmitter system. Lancet 1982; 319: 18–20.&#13;
&#13;
Schafer DF, Fowler JM, Munson PJ, Thakur AK, Waggoner JG, Jones EA. Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J Lab Clin Med 1983; 102: 870–880.&#13;
&#13;
Schmidt W, Wolf G, Grand;uuml;ngreiff K, Meier M, Reum T. Hepatic encephalopathy influences high-affinity uptake of transmitter glutamate and aspartate into the hippocampal formation. Metab Brain Dis 1990; 5: 19–31.&#13;
&#13;
Shawcross DL, Balata S, Olde Damink SWM, Hayes PC, Wardlaw J, Marshall I, et al. Low myo-inositol and high glutamine levels in brain are associated with neuropsychological deterioration after induced hyperammonemia. Am J Physiol Liver Physiol 2004; 287: G503–G509.&#13;
&#13;
Sherlock S, Summerskill WHJ, White L, Phear E. Portal-systemic encephalopathy neurological complications of liver disease. Lancet 1954; 264: 453–457.&#13;
&#13;
Song G, Dhodda VK, Blei AT, Dempsey RJ, Rao VLR. GeneChip® analysis shows altered mRNA expression of transcripts of neurotransmitter and signal transduction pathways in the cerebral cortex of portacaval shunted rats. J Neurosci Res 2002; 68: 730–737.&#13;
&#13;
Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Milette PC, et al. Increased blood manganese in cirrhotic patients: relationship to pallidal magnetic resonance signal hyperintensity and neurological symptoms. Hepatology 1996; 24: 1116–1120.&#13;
&#13;
Summerskill WHJ, Davidson EA, Sherlock S, Steiner RE. The neuropsychiatric syndrome associated with hepatic cirrhosis and an extensive portal collateral circulation. Q J Med 1956; 25: 245–266.&#13;
&#13;
Szerb JC and Butterworth RF. Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog Neurobiol 1992; 39: 135–153.&#13;
&#13;
Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, Lee WM, Blei AT, US Acute Liver Failure Study Group. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 2003; 125: 755–764.&#13;
&#13;
Vierling JM, Mokhtarani M, Brown Jr RS, Mantry P, Rockey DC, Ghabril M, et al. Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis. Clin Gastroenterol Hepatol 2016; 14: 903–906.&#13;
&#13;
Vogels BAPM, van Steynen B, Maas MAW, Jand;ouml;rning GGA, Chamuleau RAFM. The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. J Hepatol 1997; 26: 387–395.&#13;
&#13;
Wright G and Jalan R. Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora’s box? Hepatology 2007; 46: 291–294.&#13;
&#13;
Yurdaydin C, Hand;ouml;rtnagl H, Steindl P, Zimmermann C, Pifl C, Singer EA, Roth E, Ferenci P. Increased serotoninergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. Hepatology 1990; 12: 695–700.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>